Exhibit 99.1
logo11.jpg

News

FOR IMMEDIATE RELEASE
 
Media Contact Information:
Karen Kirkwood
Investor Contact Information:
Ken Apicerno
Phone: 781-622-1306
Phone: 781-622-1294
E-mail: karen.kirkwood@thermofisher.com
E-mail: ken.apicerno@thermofisher.com
Website: www.thermofisher.com
 



Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2017 Results


WALTHAM, Mass. (January 31, 2018) - Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2017.

Fourth Quarter and Full Year 2017 Highlights

Fourth quarter revenue grew 22% to $6.05 billion.

Full year revenue grew 14% to $20.92 billion.

Fourth quarter GAAP diluted earnings per share (EPS) decreased 18% to $1.30.
Full year GAAP diluted EPS increased 10% to $5.59. GAAP results include a one-time tax provision of $204 million associated with the recent enactment of tax reform legislation in the U.S.

Fourth quarter adjusted EPS increased 16% to $2.79.
Full year adjusted EPS increased 15% to $9.49.

Invested $0.9 billion in R&D during the year and launched high-impact products across all segments, highlighted by the Thermo Scientific Q-Exactive HF-X mass spectrometer, Thermo Scientific Krios G3i cryo transmission electron microscope, Applied Biosystems SeqStudio genetic analyzer and the Oncomine Dx Target Test.

Delivered strong year-over-year growth in Asia-Pacific and Emerging Markets, led by outstanding performance in China, and added new capabilities to support growth opportunities in China, South Korea and the Middle East.

Deployed $7.8 billion in 2017 on strategic acquisitions, adding leading biopharma contract development and manufacturing services through Patheon and expanding our offerings in bioproduction, cloud-based informatics, electron microscopy and transplant diagnostics.

Returned $1 billion of capital to shareholders in 2017 through stock buybacks and dividends.

Adjusted EPS, adjusted operating income, adjusted operating margin and free cash flow are non-GAAP measures that exclude certain items detailed later in this press release under the heading “Use of Non-GAAP Financial Measures.”

“We’re pleased to deliver an excellent 2017, with a very strong finish in the fourth quarter that capped off another outstanding year,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “Our performance demonstrates the continued success of our proven growth strategy and great execution by our teams.

“Among the highlights of 2017, we launched innovative new products in our key technology platforms, and enabled breakthroughs in proteomics, genetic analysis and structural biology. We continued to leverage our industry-leading scale to deliver strong performance in high-growth emerging markets, particularly China, India and South Korea. It was also a very active year for strategic M&A. We significantly enhanced our value proposition with the addition of Patheon’s leading services offering for pharma and biotech customers.”

Casper concluded, “We’re in an excellent position as we begin 2018, and we’re energized about our prospects for the future.”


Fourth Quarter 2017

Revenue for the quarter grew 22% to $6.05 billion in 2017, versus $4.95 billion in 2016. Organic revenue growth was 8%; acquisitions increased revenue by 11% and currency translation increased revenue by 3%.

GAAP Earnings Results

GAAP diluted EPS in the fourth quarter decreased to $1.30, versus $1.59 in the same quarter last year, due to the one-time tax provision previously noted. GAAP operating income for the fourth quarter of 2017 grew to $0.96 billion, compared with $0.75 billion in the fourth quarter of 2016. GAAP operating margin increased to 15.8%, compared with 15.2% in the fourth quarter of 2016.

Non-GAAP Earnings Results

Adjusted EPS in the fourth quarter of 2017 increased 16% to $2.79, versus $2.41 in the fourth quarter of 2016. Adjusted operating income for the fourth quarter of 2017 grew 18% compared with the year-ago quarter. Adjusted operating margin decreased 80 basis points to 24.0%, compared with 24.8% in the fourth quarter of 2016.


Full Year 2017

Revenue for the full year grew 14% to $20.92 billion in 2017, versus $18.27 billion in 2016. Organic revenue growth was 5%; acquisitions increased revenue by 9% and currency translation increased revenue slightly.

GAAP Earnings Results

GAAP diluted EPS for the full year increased to $5.59, versus $5.09 in 2016. GAAP diluted EPS in 2017 reflects the one-time tax provision. GAAP operating income for 2017 grew to $2.97 billion, compared with $2.45 billion a year ago. GAAP operating margin was 14.2% in 2017, compared with 13.4% in 2016.

Non-GAAP Earnings Results

Adjusted EPS for the full year rose 15% to $9.49, versus $8.27 in 2016. Adjusted operating income for 2017 grew 15% compared with 2016, and adjusted operating margin expanded 10 basis points to 23.2%, compared with 23.1% a year ago.


Annual Guidance for 2018

The company will provide 2018 financial guidance on its earnings conference call this morning at 8:30 a.m. Eastern time.


Segment Results

Management uses adjusted operating results to monitor and evaluate performance of the company’s four business segments, as highlighted below. Since these results are used for this purpose, they are also considered to be prepared in accordance with GAAP.

Life Sciences Solutions Segment

In the fourth quarter of 2017, Life Sciences Solutions Segment revenue grew 11% to $1.58 billion, compared with revenue of $1.42 billion in the fourth quarter of 2016. Segment adjusted operating margin increased to 35.6%, versus 32.9% in the 2016 quarter.

For the full year 2017, Life Sciences Solutions Segment revenue rose 8% to $5.73 billion, compared with revenue of $5.32 billion in 2016. Segment adjusted operating margin increased to 33.1% in 2017, compared with 30.0% a year ago.

Analytical Instruments Segment

Results for the Analytical Instruments Segment reflect the acquisition of FEI Company in September 2016. Segment revenue grew 16% to $1.41 billion in the fourth quarter of 2017, compared with revenue of $1.22 billion in the fourth quarter of 2016. Segment adjusted operating margin was flat at 24.5%.

For the full year 2017, Analytical Instruments Segment revenue rose 31% to $4.82 billion, compared with revenue of $3.67 billion in 2016. Segment adjusted operating margin grew to 21.3%, versus 20.3% in 2016.

Specialty Diagnostics Segment

Specialty Diagnostics Segment revenue grew 10% to $0.91 billion in the fourth quarter of 2017, compared with revenue of $0.83 billion in the fourth quarter of 2016. Segment adjusted operating margin was 26.5%, versus 27.2% in the 2016 quarter.

For the full year 2017, Specialty Diagnostics Segment revenue grew 4% to $3.49 billion, compared with revenue of $3.34 billion in 2016. Segment adjusted operating margin was 26.7%, versus 2016 results of 27.2%.

Laboratory Products and Services Segment

Laboratory Products and Services Segment results reflect the acquisition of Patheon in late August 2017. In the fourth quarter of 2017, segment revenue grew 43% to $2.40 billion, compared with revenue of $1.68 billion in the fourth quarter of 2016. Segment adjusted operating margin was 12.5%, versus 14.0% in the 2016 quarter.

For the full year 2017, Laboratory Products and Services Segment revenue grew 16% to $7.83 billion, compared with revenue of $6.72 billion in 2016. Segment adjusted operating margin was 12.9%, versus 14.4% in 2016.


Use of Non-GAAP Financial Measures

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including adjusted EPS, adjusted operating income and adjusted operating margin, which exclude certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition and significant transaction costs; restructuring and other costs/income; and amortization of acquisition-related intangible assets. Adjusted EPS also excludes certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, tax provisions/benefits related to the previous items, benefits from tax credit carryforwards, the impact of significant tax audits or events and the results of discontinued operations. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods. We also use a non-GAAP measure, free cash flow, which is operating cash flow, excluding net capital expenditures, and also excludes operating cash flows from discontinued operations to provide a view of the continuing operations’ ability to generate cash for use in acquisitions and other investing and financing activities. We believe that the use of non-GAAP measures helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company’s performance, especially when comparing such results to previous periods or forecasts.

For example:

We exclude costs and tax effects associated with restructuring activities, such as reducing overhead and consolidating facilities. We believe that the costs related to these restructuring activities are not indicative of our normal operating costs.

We exclude certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition and significant transaction costs. We exclude these costs because we do not believe they are indicative of our normal operating costs.

We exclude the expense and tax effects associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions may be allocated to intangible assets that have lives of 5 to 20 years. In 2018, based on acquisitions closed through the end of 2017, our adjusted EPS will exclude approximately $3.25 of expense for the amortization of acquisition-related intangible assets. Exclusion of the amortization expense allows comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer companies.

We also exclude certain gains/losses and related tax effects, benefits from tax credit carryforwards and the impact of significant tax audits or events (such as the effect on deferred tax balances of enacted changes in tax rates or, in 2017, the incremental impact of tax reform legislation in the U.S.), which are either isolated or cannot be expected to occur again with any predictability and that we believe are not indicative of our normal operating gains and losses. For example, we exclude gains/losses from items such as the sale of a business or real estate, gains or losses on significant litigation-related matters, gains on curtailments of pension plans, the early retirement of debt and discontinued operations.

We also report free cash flow, which is operating cash flow, excluding net capital expenditures, and also excludes operating cash flows from discontinued operations to provide a view of the continuing operations’ ability to generate cash for use in acquisitions and other investing and financing activities.

Thermo Fisher’s management uses these non-GAAP measures, in addition to GAAP financial measures, as the basis for measuring the company’s core operating performance and comparing such performance to that of prior periods and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-making and for compensation purposes.

The non-GAAP financial measures of Thermo Fisher’s results of operations and cash flows included in this press release are not meant to be considered superior to or a substitute for Thermo Fisher’s results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth in the accompanying tables. Thermo Fisher does not provide GAAP financial measures on a forward-looking basis because we are unable to predict with reasonable certainty and without unreasonable effort items such as the timing and amount of future restructuring actions and acquisition-related charges as well as gains or losses from sales of real estate and businesses, the early retirement of debt and the outcome of legal proceedings. The timing and amount of these items are uncertain and could be material to Thermo Fisher’s results computed in accordance with GAAP.


Conference Call

Thermo Fisher Scientific will hold its earnings conference call today, January 31, 2018, at 8:30 a.m. Eastern time. To listen, dial (844) 579-6824 within the U.S. or (763) 488-9145 outside the U.S. You may also listen to the call live on our website, www.thermofisher.com, by clicking on “Investors.” You will find this press release, including the accompanying reconciliation of non-GAAP financial measures and related information, in that section of our website under “Financial Results.” An audio archive of the call will be available under “Webcasts and Presentations” through Friday, February 16, 2018.


About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands - Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services - we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.


Safe Harbor Statement

The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers’ capital spending policies and government funding policies; the effect of exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, which is on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings.” While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.


###





Consolidated Statement of Income (a)(b)
 
 
 
 
 
 
 
 
 
 
Three Months Ended
 
 
December 31,
 
% of
 
December 31,
 
% of
(In millions except per share amounts)
 
2017
 
Revenues
 
2016
 
Revenues
 
 
 
 
 
 
 
 
 
Revenues
 
$
6,047

 
 
 
$
4,953

 
 
Costs and Operating Expenses:
 
 
 
 
 
 
 
 
Cost of revenues (c)
 
3,250

 
53.7
%
 
2,546

 
51.4
%
Selling, general and administrative expenses (d)
 
1,163

 
19.2
%
 
1,017

 
20.5
%
Amortization of acquisition-related intangible assets
 
441

 
7.3
%
 
376

 
7.6
%
Research and development expenses
 
233

 
3.9
%
 
213

 
4.3
%
Restructuring and other costs, net (e)
 
2

 
0.0
%
 
48

 
1.0
%
 
 
5,089

 
84.2
%
 
4,200

 
84.8
%
 
 
 
 
 
 
 
 
 
Operating Income
 
958

 
15.8
%
 
753

 
15.2
%
Interest Income
 
20

 
 
 
14

 
 
Interest Expense
 
(166
)
 
 
 
(131
)
 
 
Other Income, Net (f)
 
8

 
 
 
16

 
 
 
 
 
 
 
 
 
 
 
Income Before Income Taxes
 
820

 
 
 
652

 
 
Provision for Income Taxes (g)
 
(290
)
 
 
 
(19
)
 
 
 
 
 
 
 
 
 
 
 
Income from Continuing Operations
 
530

 
 
 
633

 
 
 
 
 
 
 
 
 
 
 
Loss from Discontinued Operations
 
(2
)
 
 
 
(3
)
 
 
 
 
 
 
 
 
 
 
 
Net Income
 
$
528

 
8.7
%
 
$
630

 
12.7
%
 
 
 
 
 
 
 
 
 
Earnings per Share from Continuing Operations:
 
 
 
 
 
 
 
 
Basic
 
$
1.32

 
 
 
$
1.60

 
 
Diluted
 
$
1.31

 
 
 
$
1.59

 
 
 
 
 
 
 
 
 
 
 
Earnings per Share:
 
 
 
 
 
 
 
 
Basic
 
$
1.32

 
 
 
$
1.60

 
 
Diluted
 
$
1.30

 
 
 
$
1.59

 
 
 
 
 
 
 
 
 
 
 
Weighted Average Shares:
 
 
 
 
 
 
 
 
Basic
 
401

 
 
 
395

 
 
Diluted
 
405

 
 
 
397

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reconciliation of Adjusted Operating Income and Adjusted Operating Margin
 
 
 
 
 
 
 
 
GAAP Operating Income (a)
 
$
958

 
15.8
%
 
$
753

 
15.2
%
Cost of Revenues Charges (c)
 
46

 
0.8
%
 
41

 
0.8
%
Selling, General and Administrative Charges, Net (d)
 
3

 
0.1
%
 
9

 
0.2
%
Restructuring and Other Costs, Net (e)
 
2

 
0.0
%
 
48

 
1.0
%
Amortization of Acquisition-related Intangible Assets
 
441

 
7.3
%
 
376

 
7.6
%
 
 
 
 
 
 
 
 
 
Adjusted Operating Income (b)
 
$
1,450

 
24.0
%
 
$
1,227

 
24.8
%
 
 
 
 
 
 
 
 
 
Reconciliation of Adjusted Net Income
 
 
 
 
 
 
 
 
GAAP Net Income (a)
 
$
528

 
 
 
$
630

 
 
Cost of Revenues Charges (c)
 
46

 
 
 
41

 
 
Selling, General and Administrative Charges, Net (d)
 
3

 
 
 
9

 
 
Restructuring and Other Costs, Net (e)
 
2

 
 
 
48

 
 
Amortization of Acquisition-related Intangible Assets
 
441

 
 
 
376

 
 
Other Income, Net (f)
 
(11
)
 
 
 
(6
)
 
 
Provision for (Benefit from) Income Taxes (g)
 
117

 
 
 
(145
)
 
 
Discontinued Operations, Net of Tax
 
2

 
 
 
3

 
 
 
 
 
 
 
 
 
 
 
Adjusted Net Income (b)
 
$
1,128

 
 
 
$
956

 
 
 
 
 
 
 
 
 
 
 
Reconciliation of Adjusted Earnings per Share
 
 
 
 
 
 
 
 
GAAP EPS (a)
 
$
1.30

 
 
 
$
1.59

 
 
Cost of Revenues Charges, Net of Tax (c)
 
0.08

 
 
 
0.06

 
 
Selling, General and Administrative Charges, Net of Tax (d)
 
0.04

 
 
 
0.01

 
 
Restructuring and Other Costs, Net of Tax (e)
 
0.02

 
 
 
0.07

 
 
Amortization of Acquisition-related Intangible Assets, Net of Tax
 
0.77

 
 
 
0.60

 
 
Other Income, Net of Tax (f)
 
(0.02
)
 
 
 
0.04

 
 
Provision for Income Taxes (g)
 
0.59

 
 
 
0.03

 
 
Discontinued Operations, Net of Tax
 
0.01

 
 
 
0.01

 
 
 
 
 
 
 
 
 
 
 
Adjusted EPS (b)
 
$
2.79

 
 
 
$
2.41

 
 
 
 
 
 
 
 
 
 
 
Reconciliation of Free Cash Flow
 
 
 
 
 
 
 
 
GAAP Net Cash Provided by Operating Activities (a)
 
$
1,866

 
 
 
$
1,205

 
 
Net Cash Provided by Discontinued Operations
 
(1
)
 
 
 
(1
)
 
 
Purchases of Property, Plant and Equipment
 
(215
)
 
 
 
(133
)
 
 
Proceeds from Sale of Property, Plant and Equipment
 
3

 
 
 
3

 
 
 
 
 
 
 
 
 
 
 
Free Cash Flow
 
$
1,653

 
 
 
$
1,074

 
 



Segment Data
 
Three Months Ended
 
 
December 31,
 
% of
 
December 31,
 
% of
(In millions)
 
2017
 
Revenues
 
2016
 
Revenues
 
 
 
 
 
 
 
 
 
Revenues
 
 
 
 
 
 
 
 
Life Sciences Solutions
 
$
1,578

 
26.1
 %
 
$
1,419

 
28.6
 %
Analytical Instruments
 
1,414

 
23.4
 %
 
1,217

 
24.6
 %
Specialty Diagnostics
 
914

 
15.1
 %
 
834

 
16.8
 %
Laboratory Products and Services
 
2,401

 
39.7
 %
 
1,681

 
33.9
 %
Eliminations
 
(260
)
 
-4.3
 %
 
(198
)
 
-3.9
 %
 
 
 
 
 
 
 
 
 
Consolidated Revenues
 
$
6,047

 
100.0
 %
 
$
4,953

 
100.0
 %
 
 
 
 
 
 
 
 
 
Operating Income and Operating Margin
 
 
 
 
 
 
 
 
Life Sciences Solutions
 
$
561

 
35.6
 %
 
$
467

 
32.9
 %
Analytical Instruments
 
346

 
24.5
 %
 
298

 
24.5
 %
Specialty Diagnostics
 
242

 
26.5
 %
 
228

 
27.2
 %
Laboratory Products and Services
 
301

 
12.5
 %
 
234

 
14.0
 %
 
 
 
 
 
 
 
 
 
Subtotal Reportable Segments
 
1,450

 
24.0
 %
 
1,227

 
24.8
 %
 
 
 
 
 
 
 
 
 
Cost of Revenues Charges (c)
 
(46
)
 
-0.8
 %
 
(41
)
 
-0.8
 %
Selling, General and Administrative Charges, Net (d)
 
(3
)
 
-0.1
 %
 
(9
)
 
-0.2
 %
Restructuring and Other Costs, Net (e)
 
(2
)
 
0.0
 %
 
(48
)
 
-1.0
 %
Amortization of Acquisition-related Intangible Assets
 
(441
)
 
-7.3
 %
 
(376
)
 
-7.6
 %
 
 
 
 
 
 
 
 
 
GAAP Operating Income (a)
 
$
958

 
15.8
 %
 
$
753

 
15.2
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) "GAAP" (reported) results were determined in accordance with U.S. generally accepted accounting principles (GAAP).
(b) Adjusted results are non-GAAP measures and, for income measures, exclude certain charges to cost of revenues (see note (c) for details); certain credits/charges to selling, general and administrative expenses (see note (d) for details); amortization of acquisition-related intangible assets; restructuring and other costs, net (see note (e) for details); certain other gains or losses that are either isolated or cannot be expected to occur again with any predictability (see note (f) for details); and the tax consequences of the preceding items and certain other tax items (see note (g) for details).
(c) Reported results in 2017 and 2016 include i) $40 and $36, respectively, of charges for the sale of inventories revalued at the date of acquisition and ii) $6 and $5, respectively, of charges to conform the accounting policies of recently acquired businesses with the company's accounting policies.
(d) Reported results in 2017 and 2016 include $13 and $9, respectively, of third-party transaction/integration costs related to recently completed acquisitions. Reported results in 2017 also includes $10 of credits from changes in estimates of contingent acquisition consideration.
(e) Reported results in 2017 and 2016 include restructuring and other costs, net, consisting principally of severance, abandoned facility and other expenses of headcount reductions within several businesses and real estate consolidations. Reported results in 2017 include $45 of net credits from litigation, $7 of hurricane response/impairment costs and $4 of net losses on the settlement/curtailment of retirement plans. Reported results in 2016 include $20 of charges for litigation, $2 of environmental remediation costs and $1 of net gains on the sale of assets and settlement of retirement plans.
(f) Reported results in 2017 include a gain of $11 on an investment. Reported results in 2016 include $3 of losses on the early extinguishment of debt and $9 of net gains on investments.
(g) Reported provision for income taxes includes i) $116 and $158 of incremental tax benefit in 2017 and 2016, respectively, for the pre-tax reconciling items between GAAP and adjusted net income; ii) $1 and $(1), in 2017 and 2016, respectively, of incremental tax benefit/(provision) from adjusting the company's non-U.S. deferred tax balances as a result of tax rate changes; and iii) $30 and $12 of incremental tax provision in 2017 and 2016, respectively, due to audit settlements. Reported provision in 2017 also includes a net provision of $204 from the effects of U.S. tax reform legislation, consisting primarily of the transition tax on deemed repatriated earnings of foreign subsidiaries, net of a benefit from adjusting the deferred tax balances for the U.S. rate reduction.
Notes:
Consolidated depreciation expense is $133 and $98 in 2017 and 2016, respectively.
 





Consolidated Statement of Income (a)(b)
 
 
 
 
 
 
 
 
 
 
Year Ended
 
 
December 31,
 
% of
 
December 31,
 
% of
(In millions except per share amounts)
 
2017
 
Revenues
 
2016
 
Revenues
 
 
 
 
 
 
 
 
 
Revenues
 
$
20,918

 
 
 
$
18,274

 
 
Costs and Operating Expenses:
 
 
 
 
 
 
 
 
Cost of revenues (c)
 
10,961

 
52.4
%
 
9,459

 
51.8
%
Selling, general and administrative expenses (d)
 
4,410

 
21.1
%
 
4,044

 
22.1
%
Amortization of acquisition-related intangible assets
 
1,594

 
7.6
%
 
1,378

 
7.5
%
Research and development expenses
 
888

 
4.2
%
 
755

 
4.1
%
Restructuring and other costs, net (e)
 
97

 
0.4
%
 
189

 
1.0
%
 
 
17,950

 
85.8
%
 
15,825

 
86.6
%
 
 
 
 
 
 
 
 
 
Operating Income
 
2,968

 
14.2
%
 
2,449

 
13.4
%
Interest Income
 
81

 
 
 
48

 
 
Interest Expense
 
(592
)
 
 
 
(469
)
 
 
Other Expense, Net (f)
 
(28
)
 
 
 
(4
)
 
 
 
 
 
 
 
 
 
 
 
Income Before Income Taxes
 
2,429

 
 
 
2,024

 
 
(Provision for) Benefit from Income Taxes (g)
 
(201
)
 
 
 
1

 
 
 
 
 
 
 
 
 
 
 
Income from Continuing Operations
 
2,228

 
 
 
2,025

 
 
 
 
 
 
 
 
 
 
 
Loss from Discontinued Operations, Net of Tax
 
(3
)
 
 
 
(3
)
 
 
 
 
 
 
 
 
 
 
 
Net Income
 
$
2,225

 
10.6
%
 
$
2,022

 
11.1
%
 
 
 
 
 
 
 
 
 
Earnings per Share from Continuing Operations:
 
 
 
 
 
 
 
 
Basic
 
$
5.65

 
 
 
$
5.13

 
 
Diluted
 
$
5.60

 
 
 
$
5.10

 
 
 
 
 
 
 
 
 
 
 
Earnings per Share:
 
 
 
 
 
 
 
 
Basic
 
$
5.64

 
 
 
$
5.12

 
 
Diluted
 
$
5.59

 
 
 
$
5.09

 
 
 
 
 
 
 
 
 
 
 
Weighted Average Shares:
 
 
 
 
 
 
 
 
Basic
 
395

 
 
 
395

 
 
Diluted
 
398

 
 
 
397

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reconciliation of Adjusted Operating Income and Adjusted Operating Margin
 
 
 
 
 
 
 
 
GAAP Operating Income (a)
 
$
2,968

 
14.2
%
 
$
2,449

 
13.4
%
Cost of Revenues Charges (c)
 
123

 
0.6
%
 
102

 
0.6
%
Selling, General and Administrative Charges, Net (d)
 
78

 
0.4
%
 
104

 
0.6
%
Restructuring and Other Costs, Net (e)
 
97

 
0.4
%
 
189

 
1.0
%
Amortization of Acquisition-related Intangible Assets
 
1,594

 
7.6
%
 
1,378

 
7.5
%
 
 
 
 
 
 
 
 
 
Adjusted Operating Income (b)
 
$
4,860

 
23.2
%
 
$
4,222

 
23.1
%
 
 
 
 
 
 
 
 
 
Reconciliation of Adjusted Net Income
 
 
 
 
 
 
 
 
GAAP Net Income (a)
 
$
2,225

 
 
 
$
2,022

 
 
Cost of Revenues Charges (c)
 
123

 
 
 
102

 
 
Selling, General and Administrative Charges, Net (d)
 
78

 
 
 
104

 
 
Restructuring and Other Costs, Net (e)
 
97

 
 
 
189

 
 
Amortization of Acquisition-related Intangible Assets
 
1,594

 
 
 
1,378

 
 
Other Expense, Net (f)
 
19

 
 
 
20

 
 
Benefit from Income Taxes (g)
 
(364
)
 
 
 
(530
)
 
 
Discontinued Operations, Net of Tax
 
3

 
 
 
3

 
 
 
 
 
 
 
 
 
 
 
Adjusted Net Income (b)
 
$
3,775

 
 
 
$
3,288

 
 
 
 
 
 
 
 
 
 
 
Reconciliation of Adjusted Earnings per Share
 
 
 
 
 
 
 
 
GAAP EPS (a)
 
$
5.59

 
 
 
$
5.09

 
 
Cost of Revenues Charges, Net of Tax (c)
 
0.21

 
 
 
0.16

 
 
Selling, General and Administrative Charges, Net of Tax (d)
 
0.17

 
 
 
0.18

 
 
Restructuring and Other Costs, Net of Tax (e)
 
0.18

 
 
 
0.30

 
 
Amortization of Acquisition-related Intangible Assets, Net of Tax
 
2.86

 
 
 
2.41

 
 
Other Expense, Net of Tax (f)
 
0.03

 
 
 
0.09

 
 
Provision for Income Taxes (g)
 
0.44

 
 
 
0.03

 
 
Discontinued Operations, Net of Tax
 
0.01

 
 
 
0.01

 
 
 
 
 
 
 
 
 
 
 
Adjusted EPS (b)
 
$
9.49

 
 
 
$
8.27

 
 
 
 
 
 
 
 
 
 
 
Reconciliation of Free Cash Flow
 
 
 
 
 
 
 
 
GAAP Net Cash Provided by Operating Activities (a)
 
$
4,005

 
 
 
$
3,258

 
 
Net Cash Used in Discontinued Operations
 
1

 
 
 
2

 
 
Purchases of Property, Plant and Equipment
 
(508
)
 
 
 
(444
)
 
 
Proceeds from Sale of Property, Plant and Equipment
 
7

 
 
 
26

 
 
 
 
 
 
 
 
 
 
 
Free Cash Flow
 
$
3,505

 
 
 
$
2,842

 
 



Segment Data
 
Year Ended
 
 
December 31,
 
% of
 
December 31,
 
% of
(In millions)
 
2017
 
Revenues
 
2016
 
Revenues
 
 
 
 
 
 
 
 
 
Revenues
 
 
 
 
 
 
 
 
Life Sciences Solutions
 
$
5,728

 
27.4
 %
 
$
5,317

 
29.1
 %
Analytical Instruments
 
4,821

 
23.0
 %
 
3,668

 
20.1
 %
Specialty Diagnostics
 
3,486

 
16.7
 %
 
3,339

 
18.3
 %
Laboratory Products and Services
 
7,825

 
37.4
 %
 
6,724

 
36.8
 %
Eliminations
 
(942
)
 
-4.5
 %
 
(774
)
 
-4.3
 %
 
 
 
 
 
 
 
 
 
Consolidated Revenues
 
$
20,918

 
100.0
 %
 
$
18,274

 
100.0
 %
 
 
 
 
 
 
 
 
 
Operating Income and Operating Margin
 
 
 
 
 
 
 
 
Life Sciences Solutions
 
$
1,896

 
33.1
 %
 
$
1,596

 
30.0
 %
Analytical Instruments
 
1,027

 
21.3
 %
 
745

 
20.3
 %
Specialty Diagnostics
 
930

 
26.7
 %
 
910

 
27.2
 %
Laboratory Products and Services
 
1,007

 
12.9
 %
 
971

 
14.4
 %
 
 
 
 
 
 
 
 
 
Subtotal Reportable Segments
 
4,860

 
23.2
 %
 
4,222

 
23.1
 %
 
 
 
 
 
 
 
 
 
Cost of Revenues Charges (c)
 
(123
)
 
-0.6
 %
 
(102
)
 
-0.6
 %
Selling, General and Administrative Charges, Net (d)
 
(78
)
 
-0.4
 %
 
(104
)
 
-0.6
 %
Restructuring and Other Costs, Net (e)
 
(97
)
 
-0.4
 %
 
(189
)
 
-1.0
 %
Amortization of Acquisition-related Intangible Assets
 
(1,594
)
 
-7.6
 %
 
(1,378
)
 
-7.5
 %
 
 
 
 
 
 
 
 
 
GAAP Operating Income (a)
 
$
2,968

 
14.2
 %
 
$
2,449

 
13.4
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) "GAAP" (reported) results were determined in accordance with U.S. generally accepted accounting principles (GAAP).
(b) Adjusted results are non-GAAP measures and, for income measures, exclude certain charges to cost of revenues (see note (c) for details); certain credits/charges to selling, general and administrative expenses (see note (d) for details); amortization of acquisition-related intangible assets; restructuring and other costs, net (see note (e) for details); certain other gains or losses that are either isolated or cannot be expected to occur again with any predictability (see note (f) for details); and the tax consequences of the preceding items and certain other tax items (see note (g) for details).
(c) Reported results in 2017 and 2016 include i) $87 and $75, respectively, of charges for the sale of inventories revalued at the date of acquisition; ii) $33 and $25 of charges to conform the accounting policies of recently acquired businesses with the company's accounting policies; and iii) $3 and $2, respectively, of accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations.
(d) Reported results in 2017 and 2016 include i) $63 and $72, respectively, of third-party transaction/integration costs related to recently completed acquisitions; ii) $(8) and $17, respectively, of (income)/charges associated with product liability litigation; iii) $6 and $8, respectively, of charges to conform the accounting policies of recently acquired businesses with the company's accounting policies; iv) $15 and $(2), respectively, of charges/(credits) from changes in estimates of contingent acquisition consideration; and v) $2 and $9, respectively, of accelerated depreciation on fixed assets to be abandoned due to integration synergies.
(e) Reported results in 2017 and 2016 include restructuring and other costs, net, consisting principally of severance, abandoned facility and other expenses of headcount reductions within several businesses and real estate consolidations. Reported results in 2017 include $27 of net credits from litigation, $6 of compensation due at an acquired business on the date of the acquisition, $7 of hurricane response/impairment costs, and $6 of net charges for the settlement/curtailment of retirement plans. Reported results in 2016 include $24 of net charges for litigation, $8 of environmental remediation costs and $6 of net gains on sales of real estate and settlement of retirement plans.
(f) Reported results in 2017 include a $32 charge related to fees paid to obtain bridge financing commitments for the acquisition of Patheon and $4 of losses on the early extinguishment of debt, offset in part by $17 of net gains from investments. Reported results in 2016 include $22 of charges related to fees paid to obtain bridge financing commitments for the acquisition of FEI, $9 of losses on the early extinguishment of debt and $2 of amortization of acquisition-related intangible assets of the company's equity-method investments, offset in part by $13 of net gains from investments.
(g) Reported provision for income taxes includes i) $538 and $543 of incremental tax benefit in 2017 and 2016, respectively, for the pre-tax reconciling items between GAAP and adjusted net income; ii) $61 and $(1) of incremental tax benefit (provision) in 2017 and 2016, respectively, from adjusting the company's non-U.S. deferred tax balances as a result of tax rate changes and iii) $31 and $12 of incremental tax provision in 2017 and 2016, respectively, due to audit settlements. Reported provision in 2017 also includes a net provision of $204 from the effects of U.S. tax reform legislation, consisting primarily of the transition tax on deemed repatriated earnings of foreign subsidiaries, net of a benefit from adjusting the deferred tax balances for the U.S. rate reduction.
Notes:
Consolidated depreciation expense is $439 and $380 in 2017 and 2016, respectively.
 





Condensed Consolidated Balance Sheet
 
 
 
 
 
 
 
 
 
 
 
December 31,
 
December 31,
(In millions)
 
2017
 
2016
 
 
 
 
 
Assets
 
 
 
 
Current Assets:
 
 
 
 
Cash and cash equivalents
 
$
1,335

 
$
786

Accounts receivable, net
 
3,879

 
3,049

Inventories
 
2,971

 
2,213

Other current assets
 
1,250

 
973

 
 
 
 
 
Total current assets
 
9,435

 
7,021

 
 
 
 
 
Property, Plant and Equipment, Net
 
4,047

 
2,578

 
 
 
 
 
Acquisition-related Intangible Assets
 
16,684

 
13,969

 
 
 
 
 
Other Assets
 
1,133

 
1,012

 
 
 
 
 
Goodwill
 
25,290

 
21,328

 
 
 
 
 
Total Assets
 
$
56,589

 
$
45,908

 
 
 
 
 
 
 
 
 
 
Liabilities and Shareholders' Equity
 
 
 
 
Current Liabilities:
 
 
 
 
Short-term obligations and current maturities of long-term obligations
 
$
2,135

 
$
1,255

Other current liabilities
 
4,861

 
3,611

 
 
 
 
 
Total current liabilities
 
6,996

 
4,866

 
 
 
 
 
Other Long-term Liabilities
 
5,307

 
4,130

 
 
 
 
 
Long-term Obligations
 
18,873

 
15,372

 
 
 
 
 
Total Shareholders' Equity
 
25,413

 
21,540

 
 
 
 
 
Total Liabilities and Shareholders' Equity
 
$
56,589

 
$
45,908





Condensed Consolidated Statement of Cash Flows
 
 
 
 
 
 
 
 
 
 
 
Year Ended
 
 
December 31,
 
December 31,
(In millions)
 
2017
 
2016
 
 
 
 
 
Operating Activities
 
 
 
 
Net income
 
$
2,225

 
$
2,022

Loss from discontinued operations
 
3

 
3

Income from continuing operations
 
2,228

 
2,025

 
 
 
 
 
Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
 
Depreciation and amortization
 
2,033

 
1,758

Change in deferred income taxes
 
(1,089
)
 
(620
)
Other non-cash expenses, net
 
349

 
275

Changes in assets and liabilities, excluding the effects of acquisitions and dispositions
 
485

 
(178
)
 
 
 
 
 
Net cash provided by continuing operations
 
4,006

 
3,260

Net cash used in discontinued operations
 
(1
)
 
(2
)
 
 
 
 
 
Net cash provided by operating activities
 
4,005

 
3,258

 
 
 
 
 
Investing Activities
 
 
 
 
Acquisitions, net of cash acquired
 
(7,226
)
 
(5,178
)
Purchases of property, plant and equipment
 
(508
)
 
(444
)
Proceeds from sale of property, plant and equipment
 
7

 
26

Other investing activities, net
 
(2
)
 
76

 
 
 
 
 
Net cash used in investing activities
 
(7,729
)
 
(5,520
)
 
 
 
 
 
Financing Activities
 
 
 
 
Net proceeds from issuance of debt
 
6,459

 
7,604

Repayment of debt
 
(3,299
)
 
(4,334
)
Net proceeds from issuance of commercial paper
 
8,380

 
9,182

Repayment of commercial paper
 
(8,514
)
 
(8,278
)
Purchases of company common stock
 
(750
)
 
(1,250
)
Dividends paid
 
(237
)
 
(238
)
Net proceeds from issuance of company common stock
 
1,690

 

Net proceeds from issuance of company common stock under employee stock plans
 
128

 
87

Other financing activities, net
 
(3
)
 
(14
)
 
 
 
 
 
Net cash provided by financing activities
 
3,854

 
2,759

 
 
 
 
 
Exchange Rate Effect on Cash
 
420

 
(152
)
 
 
 
 
 
Increase in Cash, Cash Equivalents and Restricted Cash
 
550

 
345

Cash, Cash Equivalents and Restricted Cash at Beginning of Period
 
811

 
466

 
 
 
 
 
Cash, Cash Equivalents and Restricted Cash at End of Period
 
$
1,361

 
$
811

 
 
 
 
 
 
 
 
 
 
Free Cash Flow (a)
 
$
3,505

 
$
2,842

 
 
 
 
 
 
 
 
 
 
(a) Free cash flow is net cash provided by operating activities of continuing operations less net purchases of property, plant and equipment.



View differences made from one to another to evaluate Thermo Fisher Scientific Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Thermo Fisher Scientific Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account